STM JOURNALS

Research & Reviews: A Journal of
Pharmaceutical Science

ISSN: 2229-7006
Volume 16, Issue 3, 2025
September–December
DOI (Journal): 10.37591/RRJoPS

https://journals.stmjournals.com/rrjops

Review RRJoPS

An Overview of Gene Therapy

Santosh Kumar Saw[1], Kamalesh Mistry[2,*], Dhananjay Mistry[3], Aftab Alam[3]

Abstract

Gene therapy is a revolutionary technique in medical science that seeks to cure or stop illnesses by means of introducing, altering, or silencing genes inside a patient's cells. Advancements in molecular biology, genetics, and biotechnology have markedly changed this field forward markedly changed over the last few decades. The underlying idea of gene therapy is to introduce genetic material into target cells via viral or non-viral vectors to rectify faulty genes, increase therapeutic gene expression, or dampen deleterious mutations. Initially researched as a possible treatment for monogenic diseases, like hemophilia and cystic fibrosis, gene therapy has grown to tackle more challenging ailments such as several different kinds of cancer, degenerative neurological disorders, and hereditary blindness. Further advances in medical uses have come from technologies including CRISPR-Cas9, as well as in vivo and ex vivo gene transfer. Notwithstanding favorable clinical results, important factors to consider include ethical issues as well as vector-associated toxicity and immune reactions. Governmental agencies, such in guaranteeing the safety and effectiveness of gene therapy treatments the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), have an important part to play. Gene therapy is ready to revolutionize contemporary health by providing customized and perhaps curative therapies for many inherited and acquired conditions considering ongoing scientific development.

Keywords: Gene therapy, CRISPR-Cas9, Monogenic diseases, vectors, ethical issues

INTRODUCTION

Rapidly developing, gene therapy is a medical discipline revolving around changing genetic material to cure or to protect against illness. This strategy seeks to repair genetic abnormalities, add therapeutic genes, or govern. Gene expression toward therapeutic results. Gene therapy has changed since it first came about, conquering many technical and legal ones. Novel gene editing sets in motion a new approach to treating predicates. With delivery methods and editing tools, gene therapy could totally transform how genetic problems are treated, disorders, malignant growths, and even certain contagious ones.

***Author for Correspondence**
Kamalesh Mistry
E-mail: drkamaleshmistry@gmail.com

[1]Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.
[2]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.
[3]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh, Rajasthan, India.

Received Date: March 29, 2025
Accepted Date: April 19, 2025
Published Date: June 26, 2025

Citation: Santosh Kumar Saw, Kamalesh Mistry, Dhananjay Mistry, Aftab Alam. An Overview of Gene Therapy. Research & Reviews: A Journal of Pharmaceutical Science. 2025; 16(3): 89–105p.

GENE THERAPY EXPLANATION

The introduction, deletion, or alteration of genetic material inside the cells of an individual is used to prevent or cure illness.

First, one wants to repair fundamental genetic traits, addressing the root cause of illnesses rather than just their symptoms at the molecular level, so to speak. One of several techniques generally uses gene therapy processes.

- *Gene Addition:* Adding a working gene copy to make up for one that is missing or defective.
- *Gene Silencing:* It is the suppression of protein production with RNA interference (RNAi) or antisense oligonucleotides of deleterious genes.
- *Using Techniques:* such as CRISPR-Cas9 to accurately change the DNA sequence of defective genes, Gene Editing helps us to do so.

- *Gene replacement:* replacing a defective gene with a healthier one.

Two Kinds of Gene Therapy May Be Distinguished by the Target Cells

- *Somatic Gene Therapy:* Changes genes in non-germ cells, affecting just the recipient and not their offspring.
- *Heritable Genetic Changes:* Result from germline gene therapy that alters genes in sperm, eggs, or embryos modifications issues; some nations ban it now.

BACKGROUND FROM HISTORY

Early genetic studies and developments in molecular biology gave birth to the notion of gene therapy. Several major events mark the historical progression of gene therapy:

Early Theoretical Bases (Mid-20th Century)

Following the discovery of how genes could be altered to cure diseases, the concept of gene modification was first floated in the 1960s.

In 1944, Avery, MacLeod, and McCarty showed DNA as the genetic material, and the double-helix configuration of DNA in 1953 by Watson and Crick [1] helped. Genetic disorders could be fixed; it was theorized by researchers through cellular functional gene introduction.

Initial Experimental Gene Therapy from 1990

On a four-year-old girl with severe combined, the first authorized gene therapy experiment took place in 1990. A genetic disorder caused by an ADA (adenosine deaminase) mutation; immunodeficiency. Using a retroviral vector, scientists inserted a functional ADA gene into the white blood cells of the patient, cells that partially restore the immune system [2]. This achievement showed how practical gene research is therapy for human subjects.

Improvements in Viral and Non-Viral Vectors from the Age 2000s–Present

It's been a major advance over the last 20 years in the creation of more efficient and safe devices, and gene delivery techniques consist of:

- *Common Viral Vectors:* include lentiviruses, adeno-associated viruses (AAVs), and adenoviruses, which provide great amounts of gene delivery efficiency.
- *Non-Viral Vectors:* that offer alternative include lipid nanoparticles (LNPs) and electroporation delivery ways having lower immunogenicity.

CRISPR-Cas9 and the Future of Gene Editing from 2012 to Present

By allowing exact genome editing, the discovery of CRISPR-Cas9 in 2012 fundamentally altered gene therapy. New opportunities for DNA-level therapy of genetic defects have opened thanks to this technology for treating & ongoing clinical trials for disorders such as sickle cell anemia and Duchenne muscular dystrophy [3].

Legal landmarks and FDA approvals

2017 saw the United States' First gene therapy product, Luxturna, approved by the Food and Drug Administration (FDA) to cure inherited retinal dystrophy [4]. Multiple gene therapies have been approved since then, setting the stage for more general clinical use.

WAYS BY WHICH GENE THERAPY WORKS

Modifying or controlling genes, gene therapy is a groundbreaking technique for treating genetic conditions and expression to rectify or counteract genetic defects that cause diseases. Gene substitution therapy, gene silencing (RNA- RNA-interferers, antisense agents, and other approaches – RNA- RNA-interferers), gene addition therapy, and gene editing using CRISPR-Cas 9 and other techniques.

Mechanism Has Different Molecular Strategies That Allow for Exact Genetic Treatments

Therapies Based on Gene Replacement

To replace a gene, one carries a working copy of the faulty gene directly into the cells of a patient to do so, get back regular behavior. Monogenic disorders, those in which a single gene is present, are usually treated with this approach, where a mutation results in disease.

Mechanism

Viral or non-viral vectors deliver a therapeutic gene (transgene) into the target cells. Integration into the genome or episomal presence allows for the creation of the transgene active proteins. The unique gene is introduced to compensate for, but not replace, the faulty or changed working gene. The fresh protein rectifies the underlying genetic deficiency, thus reducing disease symptoms.

Vectors Used by One

Adeno-associated virus (AAV) is a non-integrating, long-term expression in non-dividing cells [5]. Lentivirus integrates into the genome, therefore, allowing dividing cells long-term expression as in paragraph [6]. Direct DNA or mRNA delivery: lipid nanoparticles or electroporation, non-viral strategies [7].

Relevance

- Zolgensma® (onasemnogene abeparvovec) sends the SMN1 gene to Spinal Muscular Atrophy (SMA) to renew movement mechanics [8].
- *Hemophilia B:* Gene therapy transports the Factor IX gene to restore blood clotting capacity [9].

Inhibiting Genes (RNA interference, RNAi)

By means of RNA interference (RNAi) techniques, gene silencing treatment inhibits the expression of the disease. Genes causing issues. Dominant-negative diseases and disorders especially benefit from this strategy, resulting from toxic gain-of-function mutations [10, 11].

Mechanism

The cell is introduced with small interfering RNA (siRNA) or microRNA (miRNA) molecules. These chemicals direct the RNA-induced silencing complex (RISC) to attach to complementary mRNA. Degradation of the target mRNA stops protein synthesis. Downregulation of gene expression lowers pathologic protein levels.

Distributing Mechanisms

- First FDA-approved siRNA therapy for congenital, patisiran, utilizes lipid nanoparticles (LNPs).
- *hATTR, hATTR:* uetransthyretin amyloidosis.
- *Viral vectors:* Lentiviral shRNA long-term gene silencing delivery in the renal.

Applications and Research

Patisiran quiets the TTR gene to lower aggregation of misfolded transthyretin protein in amyloidosis [12]. RNAi-based treatments lower viral replication by targeting HBV RNA [13].

Therapy of Gene Addition

To offer a useful role instead, gene addition therapy brings an entirely new gene into cells, rather than fixing one that is damaged. Complex illnesses and polygenic conditions can benefit from this approach.

Process Mechanism

The target cells are changed by the addition of a novel gene, therefore, causing a new biological activity. To oppose disease pathology, the added gene could code for a therapeutic protein, enzyme, or receptor. The gene might exist episomal (AAV) or migrate into the genome (lentivirus).

Vectors Utilized

Retroviral vectors: Integrate stably into dividing cells [14]. Lepisomal AAV vectors limit the chance of insertional mutagenesis [15].

Uses

- *Targeted T-cell chimeric antigen receptor (CAR) therapy:* Synthetic CAR gene installed in T cells for specific use in cancer immunotherapy [14].
- *Cystic Fibrosis:* Lung cell chloride channel activity is restored by including a functional CFTR gene.

Editing of Genes (Methods Other Than CRISPR)

Gene editing allows for exact variations of the genome to fix genetic mutations or change gene expression. By far the most popular gene-editing technology is CRISPR-Cas9 [16–20].

Mechanism CRISPR-Cas9

Driven by a guide RNA (gRNA), the Cas9 enzyme targets a particular DNA sequence. Cas9 generates double-strand breaks (DSBs) right at the target site.

The Cell Repairs the Breakthrough

Non-homologous end joining (NHEJ) results in knockouts of genes. Using a template, homology-directed repair (HDR) adds accurate DNA changes, different gene-editing techniques: Base editing converts single nucleotides free of creating DSBs, therefore, lowering mistakes. With great accuracy, prime editing uses a reverse transcriptase to reconstruct genetic sequences.

Applications

CRISPR-based treatments target BCL11A to revive fetal hemoglobin production 20 times. CRISPR therapy corrects CEP290 mutations to restore vision in Leber Congenital Amaurosis (LCA10) [21].

VECTORS USED IN GENE THERAPY

Vectors are relied on by gene therapy to carry genetic information into target cells. These column vectors can generally be subdivided into viral and non-viral. Viral vectors take advantage of the natural virus entry mechanism. Non-viral vectors implement synthetic or physical techniques to enable gene delivery; cells are delivered by these. Every type of vector has special benefits and constraints that affect its use in research and medical contexts.

Viral Vectors

Genetically engineered viruses meant to transport therapeutic genes without producing disease are viral vectors. Efficient target cell entry of these vectors integrates or expresses the genetic payload. Among the most often employed viral vectors in gene therapy are lentiviruses, adeno-associated viruses (AAVs), retroviruses, and adenoviruses.

- *Adeno-Associated Virus:* Part of the Parvoviridae family, little, non-enveloped adeno-associated viruses (AAVs) exist. Because of their safety profile and capacity to modulate long-term gene, they are found often in gene therapy expression in non-dividing cells.
- *Action's Mechanism:* Through receptor-mediated endocytosis, AAVs penetrate cells and break the endosome to provide their single-APolynomial: nuclear stranded DNA genome. Most AAV vectors stay episomal, i.e., do not assimilate into the host, so decreasing the risk of insertional mutagenesis [22].
- *Benefits:* Immunohistologic and low toxicity gene expression over long times in non-dividing cells. Tropism for several tissues, including the brain, liver, and muscle.
- *Restrictions:* Restricted cargo space (~4.7 kb). Dependent on helper virus (adenovirus or herpesvirus) for production [23], rolling.
- *Applications:* Retinal inherited disorders (Luxturna) [24].

Lentiviridae

Retroviruses descended from human immunodeficiency virus (HIV-1) give rise to a subclass. There are outside the widely used for ex vivo gene therapy; these signed cells are then used physical body and then reinfused.

- *Mechanism of Action:* Using the viral enzyme integrase, Lentiviral vectors integrate their RNA genome into the host cell's DNA, keeping constant gene expression [25].
- *Benefit:* Transduction is possible in both dividing and non-dividing cells.
- *Limits:* Risks of mutagenesis through insertion. Oncogenesis may be possible should integration happen close to oncogenes [26].
- *Uses of the Program:* Lentiviral vectors are used in CAR-T cell therapy for leukemia and treatments of sickle cell disease (e.g., LentiGlobin) [27].

A Human-Generated Virus Subgenres

Among the first viral vectors employed in gene therapy, retroviral vectors based on murine leukemia viruses (MLVs) were those they be discovered in gene therapy. Unlike lentiviruses, which mostly affect dividing cells.

- *Mechanism of Action: By* integrating their genetic material into the host genome, retroviruses guarantee constancy of gene expression. Integration occurs randomly, though, so raising the mutational risk [28].
- *Upsides:* Genomic integration stabilizes gene expression. Proven in clinical tests.
- *Restrictions:* Ask yourself these queries. Transduction happens in only dividing cells. Greater risk of insertional mutagenesis than lentiviruses.
- *Use:* Previously utilized in gene therapy for X-linked severe combined immune deficiency (SCID-X1), though some sources differ about this. patients had leukemia since the oncogene turned on [29].

An Adenovirus

Non-enveloped double-stranded DNA viruses are often employed as transient gene signals, the adenovirus gene therapy technique.

- *Action Mechanism:* Entering cells through receptor-mediated endocytosis, adenoviruses carry their genetic material into the final nucleus without inteinto the host genome, resulting in temporary gene expression [30].
- *Benefits:* Great transduction rate. Large cargo space (approximately 36 Kb). Wide tissue tropism.
- *Constraints:* Strong immune response and inflammation. Genes with transient expression need repetitive administration.
- *Use:* Early gene therapy studies for cystic fibrosis and cancer used adenoviral vectors, albeit immune responses with these vectors were not as strong, restricting their general applications.

Nonviral Vectors

Physical or artificial systems for bringing genetic material into cells are non-viral vectors. They give you lower transfection, lower immunogenicity, and simpler production than viral vectors, but usually less transfection efficiency.

- *Lipid Nanoparticles (LNP):* Including COVID-19 vaccines, lipid nanoparticles (LNPs) are widely used for gene therapy based on mRNA.
- *Syntax of Action:* LNPs enclose nucleic acid, either DNA or mRNA, and help it to be absorbed through endocytosis. The lipid formulation assists in cytoplasmic release by avoiding endosomal degradation.
- *Upsides:* Low toxicity and high biocompatibility. Production scales and keeps expenses down. Good for delivering messenger RNA [31, 32].
- *Restriction:* Less transfection effectiveness as compared to viral vectors. Short-term activity of genes.

- *Uses:* Usage in mRNA-based vaccines, including Pfizer-BioNTech and Moderna COVID-19 shots, as well as experimental therapies for genetic disorders [33].

Corresponds to Plasmid DNA

A straightforward and inexpensive gene delivery technique is plasmid DNA (pDNA). DNA it is commonly seen in vaccines and genetic enhancement therapy.

- *Mechanism of Operations:* After cells have taken it up, plasmid DNA migrates into the nucleus and is turned into protein-encoding mRNA in combination prospectively. It does not integrate into the genome as viral vectors do [34].
- *Benefits Would Be:* There is no possibility of getting insertional mutagenesis. Long-term storage durability.
- *Constraints:* Low transfection rates within cells. physical or chemical means for cell entry (e.g., electroporation). Use everywhere and on almost everything. Experimental gene therapies for cancer and DNA vaccines (e.g., ethicalco-v for COVID-19), infectious illnesses [35].

Electroporation Proceeds

A physical technique employing electrical pulses to cause transient holes in cells is electroporation membranes which allows DNA, RNA, or proteins to penetrate cells.

- *Mechanism of Operation:* Short electrical impulses break the lipid bilayer, hence allowing nucleic acids to permeate the cytoplasm before membrane repair [36].
- *Benefits:* Great efficiency for ex vivo gene delivery. No use of viral parts.
- *Restrictions:* Potential cell damage from an elevated voltage. Limited use in vivo.
- *Uses:* Deployed in CAR-T cell therapy, DNA vaccines, and gene editing (CRISPR delivery) [37]. The use of gene therapy developments rapidly advancing, and gene therapy has great potential across different diseases. This is the definition approach that entails genetically modifying genetic material to cure or avert illnesses. The following are a few of the major uses of gene therapy in human disorders.

GENETICAL ISSUES

Gene therapy provides hope for one-gene mutations causing monogenic diseases. These approaches work by either silencing, editing, or replacing defective genes [38].

Cystic Fibrosis (CF)

Mutations in the CFTR (cystic fibrosis transmembrane cause cystic fibrosis, a genetic condition conductance regulator) gene, leading to thick mucus buildup in the lungs and other organs. Using gene therapy, possible treatments for CF are:

Functional duplicates of adeno-associated virus (AAV) and lentiviral vectors are transported in gene therapy using viral vectors lung epithelial cells will be headed by the CFTR gene, delivering CFTR mRNA for protein expression correction via mRNA therapy [39]. Gene editing: CRISPR-Cas9 technology to fix the broken CFTR gene [40].

Sickle Cell Disease (SCD)

SCD results from a mutation in the HBB gene, which produces sickle-shaped red blood cells and irregular hemoglobin levels red cells.

Gene Therapy for SCD Encompasses

- *Gene Addition Therapy:* Lentiviral-mediated delivery of operational HBB [41].
- *Gene Editing:* CRISPR-Cas9 to restore fetal hemoglobin (HbF), therefore, reducing sickling [42].
- *Stem Cell Therapy:* transplantation after ex vivo hematopoietic stem cell changes [43].

Hemophilia Aches and Hemorrhage

Mutations in the F8 and F9 genes cause hemophilia A and B, respectively, resulting in low clotting factor VIII and the remaining nine, respectively. Strategies for gene therapy run along these lines:

AAV-Based Gene Therapy

Continuous clotting-product delivery of functional F8 or F9 to liver cell makers, CRISPR gene editing: fixing the stem cells' fundamental mutations, and cancer treatment.

By allowing targeted methods, like engineered ones, gene therapy has transformed oncology treatment, oncolytic viruses, and immune cells [44, 45].

Chimeric Antigen Receptor T Cell Treatment

CAR-T therapy is when a patient's T cells are genetically modified to express a manmade receptor aiming for cancer cells. This strategy works very well for hematology cancerous forms, including lymphoma and leukemia. Some FDA-approved CAR-T therapies are tisagenlecleucel (Kymriah) for B-cell leukemia and for. Yescarta for lymphoma [46] is axicabtagene ciloleucel. Lentiviral or retrovirus vectors deliver CAR genes into T cells, which are afterwards expanded and given back by means of patients.

In Oncolytic Virus Therapy, Drugs Are Delivered into Tumor Cells

Engineered viruses kill cancer cells discriminately and then trigger an immune reaction. For instance, for melanoma, the changed herpes simplex virus talimogene laherparepvec (T-VEC) is used [47–49].

Neurological Illnesses

Whereas gene therapy is being investigated for several neuromuscular and neurodegenerative diseases, conventional approaches offer little effectiveness.

Stiff Back Muscular Atrophy (SMA)

Mutations in the SMN1 gene cause spinal muscular atrophy, a deadly neuromuscular condition. Approaches to so-called gene therapy comprise:

- *Therapy Based on AAV9:* Onasemnogene abeparvovec (Zolgensma) delivers a working SMN1 copy to muscle neurons that lengthen infants with SMA.

Huntington's Disease

A neurodegenerative disease from an enlarged repeat of the HTT gene. Gene therapy techniques consist of RNA interference: employing small interfering RNA (siRNA) to limit the expression of mutant HTT [50]. Experimental treatments aimed at mutant HTT in AAV-mediated gene silencing to slow disease progression [51].

Cardiovascular Illnesses

By encouraging vascular repair, gene therapy is coming forward as a possible therapy for heart disease, lowering cholesterol levels, and changing heart activity.

Angiogenesis therapy, by means of which VEGF genes are transmitted to stimulate fresh blood vessel development, is helping vessel creation in ischemic heart disease [52].

Cholesterol-lowering gene editing: CRISPR-based editing of PCSK9 to reduce LDL cholesterol in hypercholesterolemia [53]. Using gene therapy from stem cells to treat heart failure is myocardial regeneration [54].

Disorders in Ophthalmic

Gene therapy is especially focused on inherited retinal diseases (IRDs) since they are monogenic accessibility of the eye for vector delivery.

Luxturna Is Aimed at Genetic Blindness

An FDA-approved AAV-based gene therapy for RPE65- is voretigene neparvovec (Luxturna) connected to retinitis. By means of AAV2, a functional RPE65 gene is given to retinal cells, hence

restoring vision in Leber's sufferers. LCA (congenital amaurosis) and retinitis pigmentosa [55]. Gene therapy pharmacokinetics and pharmacodynamics. To address or prevent disease, gene therapy delivers genetic material into the cells of a patient. Knowing that optimizing efficiency depends much on the pharmacology of gene therapy Alsory (defun). Conventional pharmacokinetics emphasizes how a drug enters, spreads, and undergoes metabolism. Gene therapy is particularly difficult since it deals with nucleic acids (DNA, RNA) and excretion (ADME) delivered in non-viral vectors or using viral ones. Gene therapy is absorbed and distributed.

Gene, unlike traditional medicines that enter through the gastrointestinal (GI) tract or bloodstream, vector-based distribution techniques are the foundation of some treatments meant to target cells. The route of delivery greatly influences the distribution and absorption of the genetic code.

Way of Administration

- *IV:* Used in gene therapies for systemic diseases for intravenous delivery (e.g., hemophilia, metabolic disorders) [55]. Vector molecules, including adeno-associated viruses (AAVs) and lipoprotein particles, move through the bloodstream to many tissues [56].
- For illnesses affecting particular organs, gene therapy is administered via local delivery (intrathecal, intraocular, intramuscular). It can be given directly via spinal injections for nerve disorders such as spinal muscular atrophy [57]. Studied for dermatological and respiratory uses, inhalation or topical application would help ensure localized outcomes [58].
- *Vector Distribution System:* Viral vectors: diverse AAV serotypes have unique tropism (organ specificity), which influences biodistribution [59]. Divide on particle size, charge, and surface Non-Viral Vectors: LNPs and polymeric nanoparticles alterations [60].
- *Cell Translocation and Cellular Uptake:* Most gene vectors in gene therapy come into cells using receptor-mediated endocytosis [61]. Whereas RNA treatments need to get into the nucleus for transcription, DNA-based therapies do. In the cytoplasm, mRNA functions/render [62].

Length of Gene Expression

Small-molecule drugs are expelled over hours to days; gene therapy can have long-term effects based on immune reaction, promoter activity, and vector type.

- *Temporary vs. Permanent. Long Term Performance:* mRNA-based Therapies: Short-lived expression (hours to days) due to fast mRNA degradation [63]. Non-integrating Viral Vectors (AAV, Lentivirus): Expression lasts weeks to years, depending on episomal persistence [64]. Available gene expression for the lifetime of the cell is but with enhancing vectors (retroviruses, lentiviruses): Risks of insertional mutagenesis that might exist [65].
- *Duration Factors:* Once silenced, strong viral promoters (e.g., CMV) give great expression but may be silenced over time [66]. Genetic material is diluted by fast-dividing cells in slow-dissolving cells (e.g., bone marrow) keeps expression longer [67]. Host Immune Response: Immune-mediated clearance can reduce expression duration, particularly with viral vectors [68].

Metabolism of genetic information and clearance of it unlike conventional medicines, the removal of genetic information varies. Clearance and metabolism proceed by means of immune-mediated pathways and enzymatic breakdown [69].

Nucleic Acids Metabolic Pathway

- *RNA-Based Therapies:* mRNA is broken down by ribonucleases (RNases) in the cytoplasm within hours.
- *Over time, DNA-Based Therapies:* Non-integrated plasmid DNA is diluted or degraded in dividing cells [70].
  - *Vectors' Clearance:* Cleared by the liver from circulation, AAVs have their DNA fragments metabolized by it within cells [71].

- *Lipid Nanoparticles (LNPs):* Cleared through hepatic metabolism, with lipid parts expelled via bile or urine [72].

IMMUNE SYSTEM CLEARANCE

Recognition of foreign nucleic acids (via Toll-like receptors) sets off decay in innate immunity. Pre-existing neutralizing antibodies against AAVs will quicken clearance and lower the docked level of antibody efficacy [73, 74]. Gene editing technologies: safety, risks, and difficulties.

- *Inflammation Together with Immune Response:* Gene editing techniques, including CRISPR-Cas9, add foreign elements to the body, therefore, causing immune reactions. The immune system could identify Cas9 proteins from microorganisms as really foreign and mount an inflammatory reaction, potentially reducing the effectiveness of the therapy and resulting in unanticipated consequences [75]. Research indicates that in people with pre-existing immunity to Cas9 proteins, there can be raised levels of toxicity, which could affect treatment results [76]. Such an immune response can cause tissues for threatened, which would all follow from severe treatment in worst instances [77].

Researchers are looking into different gene-editing methods, including smaller Cas, to reduce these dangers of human-derived editing proteins and enzymes (e.g., Cas12 and Cas13) to minimize immune reaction [78].

Furthermore, encapsulation of gene-editing equipment and immunosuppressive treatments helps reroute the immune response away from muscle cells. Studies are underway on lipid nanoparticles to reduce immune response [79].

- *Genetics and Off-Target Interactions:* Among the most important dangers linked with gene editing are off-target effects, which are used for unintended applications. At places other than the desired goal, genetic changes take place. These off-target mutations may cause disruption of vital genes, genomic instability, and perhaps carcinogenic properties [80].

Though not perfect, CRISPR-Cas9, as well as other editing tools, depend on guide RNA to direct DNA sequences targeting can cause undesired changes in homologous sequences throughout the genome. Research shows that loss of functionality of vital genes, genetic disease mutations, or broadcast effects, activation of oncogenes, which raises from a safety perspective [81]. Several approaches are under investigation to increase the accuracy of gene editing, among them: Others reduce off-target effects while increasing editing errors, including high-fidelity Cas9 versions such as SpCas9-HF and eSpCas9, keeping editorial effectiveness [82].

More exact and consistent changes would be possible using base and prime editing systems that do not cause DNA with double-strand cuts [83]. Aid in the projection and identification of off-target mutations by means of genetic analyses and computational processes, raising the safety of gene-editing uses [84]. Long-term results and moral questions, because gene editing is quite recently appearing, the effects over time are mostly not known these technical developments. Concerns encompass the possibility of inadvertent genetic changes being transmitted to future mutations over time, risk of unintended consequences, and next generations (germline editing) are all present changes in gene regulation caused by epigenetic markers [85].

Furthermore, more in the germline editing process, whereby genetic alterations can be made, ethical issues present themselves transmitted. This brings up a consent issue as the next generations would not be able to change forced on top of people. Furthermore, gene editing offers the possibility that social inequities are only available to the rich, therefore, opening the way to “designer babies” and genetic growth that could compound societal inequalities.

Including the World Health Organization (WHO) and the National Academy of Sciences, regulatory agencies are recommending a worldwide moratorium on heritable genome editing until it is known

more about its long-term effects term affects and moral issues [86, 87]. Current debates in bioethics underscore the requirement of clear rules, public involvement, and close monitoring to guarantee honorable gene-editing use techniques [88].

- *Legal Issues or Constraints:* Because of their unusual nature, regulatory acceptance of gene-editing platforms is a difficult and changing process for these innovations. International agreement is challenged by different countries' different rules. Though the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have protocols for gene therapies, they encounter issues in evaluating long-term effectiveness, side effects, and rising markers of toxicology and ethical issues [89].

Regulating Is Challenging Because

Defining Ethical Limits

Differentiating between therapeutic uses, say treating genetic traits, and ethical bounds as well as improvements (e.g., increasing intelligence or physical prowess [90]. Unlike typical medications, gene-editing treatments could be subject to permanent effects, needing long-term patient follow-up to evaluate unintended results [91].

- *International Cooperation:* To keep unethical, it is critical to harmonize rules across nations' applications and guarantee fair access to treatments [92]. Global regulatory agencies are creating rules stressing safety to tackle these obstacles. Knowledgeable permission and open clinical trials. Current debates concerning worldwide agreements and legalities balance innovation with morality; frameworks seek to regularize gene-editing laws' responsibility [93]. Regulation scenario and authorized documents.

To guarantee their safety, power, and quality, gene therapies must be subjected to rigorous regulatory inspection before being marketed. The two major regulatory gene therapy approvals are the two. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Gene Technologies Given EMA and FDA Approvals

Food and Drug Administration Approval Path for Gene Therapy

Gene therapy under the Center for Biologics Evaluation and Research (CBER) falls under the control of the FDA. Tissues and Advanced Therapies Office points. Biologics and gene therapy goods are the term that should first meet the requirements of Investigational New Drug (IND) before moving to clinical practice experiments [94]. The approval process involves:

Laboratory and animal experiments to determine efficacy and safety in preclinical research.

- *IND Application:* FDA submission for starting human studies. For human subjects, clinical trials *(Phases I–III)* entail a thorough assessment. A manufacturer submits, if clinical studies are positive, a Biologics License Application (BLA) for full market acceptance [95].
- *Phase IV:* Constant monitoring to follow long-term safety and efficacy. Among the more noteworthy FDA-approved gene therapies are:

The initial gene therapy for inherited eye disease approved by the FDA is Luxturna (voretigene neparvovec). (2017) [96]. Approved for spinal muscular atrophy (2019), Zolgensma (onasemnogene abeparvovec-xioi) [97]. In 2021, a CAR-T cell therapy for multiple myeloma was abecma (idecabtagene vicleucel).

The EMA Approval Process for Gene Therapies Proceeds

Gene therapy items are evaluated by the EMA by means of the Committee for – something in the European Union [98]. Human medicinal products in use (CHMP) based on technical input from the Advanced Research Data from the Committee on Advanced Use for Human Therapeutic techniques (CAT) [99]. Approved by means of screening the way passes.

- *The Advanced Therapy Medicinal Product (ATMP) Classification:* Gene therapy falls under the provisions of gene medicinal product European Union legislation.
- *Approval of Clinical Trials:* Good clinical developers have to present a Clinical Trial Application (CTA), GCP directives [100]. Companies present an MAA after the completion of clinical trials to the EMA. Approved by the European Commission, EU-wide marketing permission is issued. Gene therapies authorized by the EMA running from Strimvelis is the first ex vivo stem cell gene therapy for ADA-SCID (2016) [101]. A 2019 gene therapy for beta-thalassemia is Zynteglo (betibeglogene autotemcel) [102]. Granted for metachromatic leukodystrophy (2020) [103] Libmeldy (atidarsagene autotemcel).

Phases of Gene Therapy in Clinical Trials

Multi-phase testing of gene therapy experiments helps to assess their safety and effectiveness.

- *Phase I:* Dosage Evaluation and Safety Run on a small group of 20–100 people [104]. Evaluates dosage, effects, and safety. Establishes the first immunity reaction against the treatment.
- *Phase II:* Efficiency and Side Effects Deals with 100–300 patients having the desired condition [105]. Emphasizes first efficacy and dosage adjustment. Evaluates biological activity and short-term side effects.
- *Phase III:* Extensive Safety and Efficacy Evaluation on a Massive Scale Involves 1,000+ patients to verify effectiveness [106]. Compares gene therapy with other available treatments. The sponsor can apply for approval by means of a BLA (FDA) or an MAA (EMA) if things go as planned.
- *Phase IV:* Posting marketing surveillance. Done after permission to keep track of long-term safety and performance [107–110]. Finds uncommon side effects and sees to it that rules are still met.

Gene Therapy from an Ethical and Legal Viewpoint

Ethical Concerns

1. *Informed Consent:* Guaranteeing patients have a complete understanding of the advantages and drawbacks.
2. *Germline Editing:* Altering genes in embryos is contentious since they could lead to heritable changes.
3. *Equitable Access:* Concerns about gene-therapy cost help to raise questions of accessibility and affordability.
4. *Unforeseen Genetic Consequences:* off-target mutations should be carefully examined [111].

Legal and Regulatory Obstacles in Section

1. Legal compliance, including that of HIPAA (U.S.) and GDPR (EU), is needed for genetic material and data privacy [112, 113].
2. *Ethical Use of CRISPR Technology:* Human genome editing regulation differs across countries. Compassionate Use Programs: Permit patients without options access to experimental treatments [114]. Developments and future directions in gene editing and therapy.

Next-Generation Genetic Editing Technologies

Recent improvements in gene editing techniques have gone beyond the familiar CRISPR-Cas9. System. more accurate and faster means of changing come from groundbreaking technologies like prime editing and base editing genetic material without producing double-strand breaks (DSBs) [115].

Prime Editing Mode

Developed as a sophisticated replacement of conventional CRISPR, prime modification allows for specific insertions and deletions, base changes without needing donor DNA templates, or DSBs. Using this approach helps to reduce off-target genetic changes and enhances editing accuracy, hence making it a promising instrument for therapeutic genetic diseases like sickle cell disease and cystic fibrosis [116].

Base Editing

Direct contact of a DNA base with base editing changes one DNA base to another, free of double-stranded breaks. Cytosine, as well as highly specific adenine base editors, makes it possible to fix single

mutations. responsible for several genetic diseases [117]. Base editing, unlike traditional CRISPR approaches, does not transform; base editing reduces the possibility of unsolicited genetic damage by depending on the repair processes of the cell.

One point three CRISPR 3.0 and Epigenetic Editing. Latest advances, such as CRISPR 3.0, broaden editing possibilities to cover epigenetic changes. With these methods, scientists may control gene expression and not change the DNA sequence itself, presenting a reversible and less risky method for medical use [118].

Gene Therapy Techniques Customized for Individual Needs

The rise of gene therapy has seen a shift towards very personal therapies tailored to a person's genetic makeup. Single-cell sequencing, artificial intelligence (AI), and bioinformatics developments are then transforming the way treatments are developed and improved [119].

Individualized Gene Therapies

The incorporation of next-generation sequencing (NGS) enables accurate identification of genetic mutations. independent in particular people. Modified a person's particular gene therapy, such as CAR-T cell therapy, for cancer patients' own immune cells to target tumors more successfully [120].

In Vivo vs. Gene Replacement Outside of Vivo

In vivo gene therapy delivers useful DNA into a patient's body directly using viral or non-viral vectors. vectors with viral nature. Ex vivo methods entail changing a patient's cells outside the body prior to being reintroduced. Including lipid nanoparticles and other non-viral delivery means, modern advancements have been made in this field of electroporation, therefore, improving safety and efficacy [121].

Gene Therapy in AI and Computational Biology

Importantly aiding in the development of personalized therapies are AI-driven computational biology, by itself, optimizes guide RNA sequences for CRISPR-based treatments and predicts off-target effects.

Mechanism

Also contributing to the finding of fresh medicinal targets is the fast pace of learning models [122].

Access and Cost Decreasing

Although gene editing has great therapeutic value, it is slowed by the prevalent use of inmedications in high expenses and restricted availability. Working to create affordable treatments, researchers and biotechnology firms are providing effective answers to reduce the prices of gene treatments.

Lowering the Price of CRISPR-Based Treatments

The complexity of producing viral vectors and manufacturing gene editing treatments keeps their price high, performing field experiments. Non-viral delivery techniques, including lipid nanoparticles and cost-effective options that might lower therapy costs, are emerging for extracellular vesicles [121–124].

Automated and Scalable Manufacturing

Reducing manufacturing costs depends on scalable bioprocessing methods and automation. Let's investigate businesses and their privacy usage are putting money into large-scale CRISPR gene therapy production systems to bring down the cost per treatment and make it more widely available [125].

Broadening Worldwide Reach

Efforts to provide gene therapy in low- and middle-class nations – sometimes called lower- and middle-income countries – comprise decentralized treatment centers and inexpensive diagnostic aids. Government partnerships, academic organizations, and biotech companies are necessary to guarantee fair sharing of these life technologies used for saving [126].

FINAL REMARKS (CONCLUSION)

Offering precise and long-range responses, gene therapy has become a revolutionary method in pharmacology for long-term therapies for genetic disorders, tumors, and other chronic conditions. This domain uses methods of including gene editing, viral and non-viral vector delivery, and personalized medicine to help improve therapy effectiveness while reducing side effects.

The future of gene therapy in pharmacology is very promising. CRISPR developments and other gene-editing tools are laying the groundwork for more accurate and less risky treatments. The drug discovery should be sped up by increasing the integration of bioinformatics and artificial intelligence, and improving therapeutic approaches. But difficulties, including ethical questions, legislation difficulties, and high therapy costs, would have to be tackled to guarantee general acceptance and availability.

Gene therapy will probably transform pharmacy by offering curative means as studies develop & treatment of formerly untreatable conditions, bettering finally patient results and changing the landscape of the terrain of present-day medical science.

REFERENCES

1. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med. 1944;79(2):137–158.
2. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-deficient SCID. Science. 1995;270(5235):475–480.
3. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821.
4. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (Luxturna) in patients with inherited retinal dystrophy. Lancet. 2017;390(10097):849–860.
5. Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR. Adeno-associated virus gene therapy for rare diseases: A review. Hum Gene Ther. 2017;28(4):285–301.
6. Milone MC, O'Doherty U. Lentiviral vectors for gene therapy. Blood. 2013;122(17):1–10.
7. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
8. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
9. George LA, Sullivan SK, Giermasz A, Rasko JE, Samelson-Jones BJ, Ducore J, et al. Hemophilia gene therapy using AAV vector. N Engl J Med. 2017;377(23):2215–2227.
10. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
11. Grimm D, Kay MA. RNA interference: Gene silencing in therapy. Hum Gene Ther. 2006;17(11):1055–1061.
12. Wood MJA, Gait MJ, Yin H. RNAi therapeutics – Current status and future directions. Nat Rev Genet. 2013;14(6):1–13.
13. Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, et al. RNA interference therapy for chronic hepatitis B infection. Lancet Gastroenterol Hepatol. 2018;3(12):1–9.
14. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. Gene therapy for severe combined immunodeficiency using retroviral vectors. Science. 2002;296(5577):2410–2413.
15. Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, et al. Gene therapy using adeno-associated virus vectors in metabolic disorders. J Inherit Metab Dis. 2017;40(3):497–507.
16. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T-cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
17. Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomized, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):684–691.
18. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–471.

19. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–157.
20. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260.
21. Editas Medicine. CRISPR therapy for Leber congenital amaurosis. Clin Trials. 2020.
22. Srivastava A, Mendez B, Chamberlain W. Adeno-associated virus (AAV) vectors in gene therapy: Mechanisms and clinical applications. Mol Ther. 2020;28(3):529–547.
23. Wang D, Tai PW, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378.
24. U.S. Food and Drug Administration. Approved cellular and gene therapy products. FDA. Available from: https://www.fda.gov. Accessed March 2025.
25. Naldini L. Gene therapy returns to the front line. Nat Rev Genet. 2020;21(8):415–416.
26. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415–419.
27. Thompson AA, Walters MC, Kwiatkowski J, Rasko JE, Ribeil JA, Hongeng S, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479–1493.
28. Verma IM, Weitzman MD. Gene therapy: Twenty-first century medicine. Annu Rev Biochem. 2005;74:711–38.
29. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151.
30. Kovesdi I, Hedley SJ. Adenoviral vectors for gene therapy. Biochem J. 2010;432(3):409–418.
31. Crystal RG. Adenovirus: The first effective in vivo gene delivery vector. Hum Gene Ther. 2014;25(1):3–11.
32. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.
33. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
34. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949):1465–1468.
35. Sharma R, Anderson D, Singh P, Sarkar D, Sinha S, Singh AK, et al. Zydus Cadila's plasmid DNA COVID-19 vaccine: Mechanisms and clinical data. Front Immunol. 2022;13:873079.
36. Escoffre JM, Portet T, Wasungu L, Teissié J, Dean D, Rols MP. What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues? Biochim Biophys Acta. 2009;1809(3):209–215.
37. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.
38. Alton EWFW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, et al. A randomised, double-blind, placebo-controlled phase 2b trial of a gene therapy for cystic fibrosis. Lancet Respir Med. 2017;5(2):107–118.
39. Boucher RC. Gene therapy for cystic fibrosis: On the horizon. N Engl J Med. 2020;382(22):2141–9.
40. Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Opin Pharmacol. 2021;60:42–49.
41. Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Seilles E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855.
42. Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260.
43. Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin L, et al. Gene therapy for sickle cell disease: The bluebird bio approach. Blood Adv. 2022;6(20):5894–5903.
44. George LA, Sullivan SK, Giermasz A, Rasko JE, Samelson-Jones BJ, Ducore J, et al. Hemophilia gene therapy using AAV5. N Engl J Med. 2017;377(23):2215–2227.
45. High KA, Roncarolo MG. Gene therapy for hemophilia: The end of the beginning. N Engl J Med. 2019;381(20):1943–1945.

46. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer MW, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448.
47. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell therapy for hematologic malignancies. Science. 2018;359(6382):1361–1365.
48. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788.
49. Mendell JR, Al-Zaidy SA, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Gene therapy for spinal muscular atrophy: The Zolgensma trial. N Engl J Med. 2017;377(18):1713–1722.
50. McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, et al. Gene therapy approaches for Huntington's disease. Mol Ther. 2019;27(5):926–945.
51. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, et al. HTT silencing by antisense oligonucleotides. Nature. 2012;486(7402):739–743.
52. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. Therapeutic angiogenesis with VEGF. Circulation. 2003;107(12):1725–1732.
53. Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9. Science. 2021;373(6561):1537–1543.
54. Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Frisén J, et al. Cardiac regeneration therapies: A clinical perspective. Circ Res. 2017;120(9):e132–148.
55. Kay MA. Gene therapy: The road ahead. Nature. 2011;475(7356):462–468.
56. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78(12):6381–6388.
57. Mendell JR, Al-Zaidy SA, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
58. Hoy SM. Onasemnogene abeparvovec: First global approval. Drugs. 2019;79(11):1255–1262.
59. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: Poised at the clinical crossroads. Mol Ther. 2012;20(4):699–708.
60. Patel S, Ashwanikumar N, Robinson E, DuRoss A, Sun C, Murphy-Benenato KE, et al. Boosting intracellular delivery of lipid nanoparticles with ionizable lipids. Nat Biotechnol. 2020;38(8):1009–1019.
61. Xie J, Xie Q, Zhang H, Ameres SL, Hung ME, Mu X, et al. Engineering AAV for improved CNS transduction. Mol Ther. 2021;29(9):2823–2833.
62. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
63. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA enhances translation and reduces immunogenicity. Mol Ther. 2008;16(11):1833–1840.
64. Greig JA, Nordin JM, Alphen F, Limberis MP, Wilson JM. Persistence of AAV-mediated gene expression: Impact of epigenetics and vector genome fate. Mol Ther. 2017;25(7):1716–1730.
65. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–3142.
66. Vink CA, Gaspar HB, Gabriel R, Schmidt M, McIvor RS, Thrasher AJ, et al. Sleeping Beauty transposon-mediated autologous T-cell therapy for metastatic melanoma. J Clin Invest. 2013;123(9):4034–4048.
67. Kay MA. State-of-the-art gene-based therapies: The road ahead. Nat Rev Genet. 2011;12(5):316–28.
68. Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104.
69. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
70. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358–378.
71. Chandler RJ, Venditti CP. Gene therapy for metabolic diseases. Transl Sci Rare Dis. 2016;1(1):73–89.
72. Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A novel lipid nanoparticle for efficient mRNA delivery in vivo. Mol Ther. 2018;26(6):1509–1519.

73. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637–650.
74. Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: The challenge of translational research. J Clin Invest. 2013;123(5):2204–2208.
75. Doudna JA, Charpentier E. The new frontier of gene editing. Science. 2014;346(6213):1258096.
76. Wagner DL, Amini L, Wendering DJ, Burkhardt LM, Akyüz L, Reinke P, et al. High prevalence of Cas9-specific T cells in humans. Nat Med. 2019;25(2):242–249.
77. Charlesworth CT, Deshpande PS, Dever DP, Dejene BT, Gomez-Ospina N, Mantri S, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):267–273.
78. Smargon AA, Cox DBT, Pyzocha NK, Zheng K, Slaymaker IM, Gootenberg JS, et al. Cas13a: A new family of RNA-guided RNA endonucleases. Science. 2017;356(6338):438–442.
79. Miller JB, Zhang S, Kos P, Xiong H, Zhou K, Perelman SS, et al. Lipid nanoparticle delivery of CRISPR-Cas9 mRNA for therapy. Nat Biotechnol. 2017;35(12):1179–1187.
80. Kosicki M, Tomberg K, Bradley A. Indel mutations introduced by CRISPR-Cas9 can interfere with tumor suppressor genes. Nat Genet. 2018;50(12):1647–1653.
81. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. CRISPR-Cas9 targeted genome editing induces unexpected mutations. Nat Biotechnol. 2013;31(9):822–826.
82. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases improve genome editing specificity. Nat Biotechnol. 2016;34(8):869–874.
83. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, et al. Programmable base editing of A·T to G·C in genomic DNA without double-strand breaks. Nature. 2017;551(7681):464–471.
84. Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianne J, Renaud JB, et al. Evaluating CRISPR-Cas9 genome editing outcomes with computational tools. Genome Biol. 2016;17(1):1–14.
85. Tang L, Zeng Y, Du H, Gong M, Peng J, Zhang B, et al. CRISPR-mediated human embryo editing raises long-term safety concerns. Nature. 2017;546(7658):181–186.
86. Gyngell C, Douglas T, Savulescu J. Germline gene editing and the ethics of human enhancement. J Med Ethics. 2019;45(8):514–520.
87. National Academy of Sciences. “Human Genome Editing: Science, Ethics, and Governance.” 2017.
88. World Health Organization. “Recommendations on Human Genome Editing.” 2021.
89. FDA. “Guidelines for Gene Therapy Development”. 2021.
90. EMA. “Regulatory Perspectives on Genome Editing.” 2022.
91. Ishii T. “Regulatory Approaches for Genome-Edited Human Embryos.” Nat Biotechnol. 2017;35(1):22–24.
92. Ledford H. How will the world regulate CRISPR babies? Nature. 2019;567(7747):289–292.
93. Baylis F, et al. International consensus on gene editing regulation. The Lancet. 2020;395(10237):820–822.
94. FDA. “Guidance for Industry: Gene Therapy Clinical Trials.” 2022.
95. CBER. “Investigational New Drug Applications.” FDA. 2023.
96. Spark Therapeutics, “Luxturna Approval.” 2017.
97. Novartis. “Zolgensma FDA Approval.” 2019.
98. Bristol Myers Squibb. “Abecma Approval.” 2021.
99. EMA. “Committee for Advanced Therapies (CAT) Overview.” 2022.
100. European Commission. “Clinical Trial Regulation EU No 536/2014.” 2023.
101. Orchard Therapeutics. “Strimvelis Approval.” 2016.
102. Bluebird Bio. “Zynteglo Market Authorization.” 2019.
103. EMA. “Libmeldy Approval.” 2020.
104. NIH. “Phase I Clinical Trials Overview.” 2023.
105. FDA. “Clinical Trial Phases.” 2022.
106. EMA. “Phase III Trials: Approval Criteria.” 2023.
107. WHO. “Post-Marketing Surveillance of Gene Therapies.” 2022.
108. NCBI. “Ethics of Gene Therapy: A Review.” 2021.
109. UNESCO. “Germline Editing and Human Rights.” 2020.
110. Nature. “Gene Therapy Costs and Accessibility Challenges.” 2023.
111. CRISPR Journal. “Off-Target Effects in Genome Editing.” 2022.

112. European Data Protection Board. “Genetic Data and GDPR Compliance.” 2023.
113. Science. “CRISPR Regulation in Different Countries.” 2022.
114. FDA. “Expanded Access Programs for Gene Therapy.” 2023.
115. Doudna JA, Charpentier E. The new frontier of genome editing. Science. 2020;370(6513):361–366.
116. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–157.
117. Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420–424.
118. Liu Y, Yu C, Dai X. Epigenetic gene regulation via CRISPR-based systems. Nat Biotechnol. 2023;41(4):298–309.
119. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
120. June CH, Sadelain M. Chimeric antigen receptor T-cell therapy. N Engl J Med. 2018;379(1):64–73.
121. Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493–502.
122. Choudhury A, Rayan NA, et al. AI in genome editing: Challenges and opportunities. Nat Rev Genet. 2020;21(9):609–627.
123. Mullin E. The cost of CRISPR therapies: Balancing innovation and affordability. MIT Technol Rev. 2022.
124. Wang H, Gao X. Advances in non-viral delivery of CRISPR-based therapeutics. Nat Rev Drug Discov. 2023;22(1):22–41.
125. Tan W, Carlson-Stevermer J, et al. Scalable manufacturing of CRISPR gene therapies. Cell Rep Med. 2023;4(3):100948.
126. Kafri R, Lanphier E. Expanding access to gene therapies: Strategies for global implementation. Nat Med. 2022;28(11):2031–2043.

